Nectin-4 is an important target that has been shown to be available as a treatment for locally advanced and advanced bladder cancer. Based on this, Padcev (enfortumab-vedotin-ejfv), the first ADC drug (antibody-coupled drug) for uroepithelial carcinoma, has also received accelerated FDA approval for the treatment of locally advanced or advanced bladder cancer in patients who have previously received immune checkpoint inhibitors (PD-L1, PD-1) and platinum-containing chemotherapy before surgery (neoadjuvant therapy) or after surgery (adjuvant therapy). Adult patients with advanced or late-stage uroepithelial carcinoma (a common type of bladder cancer).
"Cancer"
-
-
There are many diseases that may recur after treatment, so many head and neck cancer patients are worried about such a situation, and their frequent ruminations may cause a lot of psychological stress to them.
-
Medical
New Research: Cracking The Targeted Drug Resistance Puzzle And Eliminating Cancer Cells Before They Evolve!
Many lung cancer patients will be detected by genetic testing to carry an EGFR mutation, and these patients can often control their tumours with EGFR-targeted drugs. Although targeted drugs are effective and have fewer side effects than chemotherapy, resistance to them inevitably occurs, after which they no longer work.
-
Apparatus
New Targeted Drug For Leukaemia Approved, 35% Of Patients' Cancer Cells Disappear Completely!
The US FDA has approved a new leukaemia drug, Olutasidenib, which has been shown to be effective and has a controlled safety profile, resulting in the complete disappearance of cancer cells in 35% of patients enrolled, with efficacy lasting up to 25.9 months.
-
Disease
Can I Have Surgery For Advanced Pancreatic Cancer? What Should I Do If I Have Advanced Pancreatic Cancer That Is Inoperable?
If pancreatic cancer is not treated in time, it will develop and become more and more serious as the disease progresses, and because the symptoms of pancreatic cancer are sometimes not obvious in the early stages of the disease, the disease is diagnosed in the middle and late stages.
-
Targeted drug Selpercatinib has received accelerated approval from the FDA. It is cancer-independent and may benefit any solid tumour with a positive RET gene fusion. It is up to 84% effective in selected patients with non-small cell lung cancer!
-
Apparatus
Significantly Longer Survival In Refractory Breast Cancer With The Addition Of Eganelisib To Standard Treatment!
Data from a trial show that adding the new drug Eganelisib to standard treatment significantly improves the length of survival for patients with triple-negative breast cancer whose disease remains unexacerbated. Patients benefited regardless of their PD-L1 status.
-
On November 4, 2022, the U.S. FDA has approved the marketing of mivituximab soratansine (Elahere), a cutting-edge antibody-coupled drug targeting folate receptor alpha (FRα), for the treatment of adult patients with epithelial ovarian, fallopian tube or primary peritoneal cancer who have received one to three systemic treatment regimens and are folate receptor alpha (FRα)-positive and platinum-resistant.
-
Apparatus
New Findings Confirm: Excellent Data On This Bipotent Antibody Drug Against Ovarian Cancer!
The results of a new study show that Ubamatamab, a bispecific antibody drug, has shown excellent results and a good safety profile in patients with ovarian cancer.
-
Disease
What Is The Difference Between Laryngeal Cancer And Pharyngitis? What Is The Way To Confirm The Diagnosis Of Laryngeal Cancer?
Both laryngeal cancer and laryngitis are common diseases, but there are some differences between these two diseases. Therefore, it is necessary for us to learn more about the common knowledge of laryngeal cancer and laryngitis, which can help us to prevent and detect the diseases.